Eli Lilly’s New Weight-Loss Treatment Shows Promising Results

The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing shots and pills from both Lilly and Novo Nordisk.

In recent years, GLP-1 receptor agonists have become a major focus in discussions around biohacking, longevity and wellness – but they’re not without a multitude of side effects.

Eli Lilly is reporting promising results for the first drug to target three hormones related to weight loss—not just one or two, as current GLP-1 drugs do.

In Eli Lilly’s phase three trial, 2,339 adults who have obesity or are overweight, have at least one weight-related comorbidity, and have no diabetes were randomized to receive retatrutide in doses of 4mg, 9mg, 12mg, or a placebo.